Research Center: Texas Center for Drug Development
Location: 6550 Mapleridge St., Suite 201, Houston, TX
Lead Doctor: Shonna Piegari, MD

Background

Major depressive disorder (MDD) can affect many areas of a person’s life. Being one of the most common disorders,  in 2015, nearly 7 percent of Americans over age 18 had an episode of MDD. MDD impacts mood and behavior as well as various physical functions, such as appetite and sleep. While there are options available, many patients can become resistant to treatment and not feel as if they have a relief from their depression symptoms.

This study explores a new investigational medication to understand if when used in conjunction with a person’s current antidepressant treatment, if it can help to relieve symptoms and be a safe option for those who do not feel relief on their current treatment.

This study seeks men and women who currently suffer from MDD and are taking antidepressants. Participants are required to attend 9 study visits at the research site over a 7 month period and will be reimbursed $80 per completed visit ($720 in total) for travel and related expenses.

Why Participate?

• You may experience an improvement in your depression symptoms
• You will be reimbursed $80 per completed visit ($720 total) for travel and related expenses.
• You will be helping to advance medical research.

Your Rights

• If you decide to participate in the study and later feel that you no longer wish to be part of it, you may withdraw at any time.
• Your records relating to this study and any other information received will be kept strictly confidential, except as required by the law.
• Qualified health professionals will monitor your health as it relates to the study.

Who Can Participate?

• Men and women aged 18-70 who have been formally diagnosed with MDD
• Currently feel depressed despite taking an antidepressant
• Have had an inadequate response to at least 1 but no more than 3 antidepressant treatments that has been taken for at least 1 month
• Women must be of non-childbearing potential (postmenopausal for 12 months, hysterectomy, bilateral salpingectomy, bilateral tubal occlusion, bilateral tubal ligation, bilateral oophorectomy)
• Able to attend 9 study visits at the research site over approximately 7 months